NECTIN2 exhibits pan-cellular expression across cancer, stromal, and myeloid cells, while TIGIT is specifically enriched in CD8+ exhausted T cells and Tregs—a heterogeneity invisible to bulk sequencing. Here, CD8A is linked to cancer.